

**Table 1 Patient characteristics**

		<b>N*</b>
<b>Patient No.</b>		10
<b>Patients evaluable for response</b>		10
<b>Age (median/ range)</b>	63/ 37-74	
<b>Sex</b>	female	4
	male	6
<b>metastatic sites</b>	1	1
	2	5
	≥3	4
	only lung	0
	lungs	7
	lymph nodes	5
	liver	2
	bone	4
	soft tissue	1
	kidney	2
	other	2
<b>tumor nephrectomy</b>		10
<b>time intervall between primary diagnosis and diagnosis of metastases</b>	≤ 12 mo.	3
	≥ 24 mo.	4
	synchronous	3
	unknown	0
<b>risk group**</b>	good/	0
	intermediate	9
	poor	1

\* number of patients

\*\* risk group according to MSKCC

**Table 2 IFN- $\gamma$  secretion of PBMC from patients and healthy donors (HD) after stimulation with PMA or HLA-A2-restricted viral peptides (CEF) as measured by IFN- $\gamma$  ELISpot (in spots per  $3 \times 10^5$  PBMC)**

<b>Pt.#</b>	<b>PMA (HD)</b>	<b>PMA* (patients)</b>	<b>CEF* (patients)</b>
#1	>1000	8/7	n.a./ n.a.
#2	>1000	12/75	1/3
#3	>1000	12/55	1/1
#4	>1000	16/203	0/1
#5	>1000	> 600/>1000	541/728
#6	>1000	17/7	n.a./ n.a.
#7	>1000	>1000/>1000	475/405
#8	>1000	1216/252	4/0
#9	>1000	n.a./>1000	61/138
#10	>1000	15/59	10/2

\* Data represent values pre/post vaccination with the post vaccination sample taken after the last immunization. PBMC from healthy donors (HD) were used as positive control in each assay.

n.a.= not available

**Table 3      Percent TSDR<sup>+</sup> CD4-T cells in peripheral blood of patients before and during vaccination**

<b>Pt.#</b>	<b>before</b>	<b>TP1</b>	<b>TP2</b>	<b>TP3</b>	<b>TP4</b>
#1	3.4	2.9	2.0	1.4	3.3
#2	3.8	7.5			
#3	5.5	6.6	4.1	3.5	2.0
#4	4.7	6.4	6.8	7.0	7.4
#5	0.2	2.9	4.5	5.8	
#6	13.7	8.4	8.4		
#7	4.3	7.9			
#8	3.1	0.1	6.7	4.5	3.6
#9	2.9	6.4	2.5	2.8	3.1
#10	7.3	2.2	5.9	4.9	

mean % TSDR+ CD4-T cells (patients before vaccination):      4.9 ±3.4%  
 mean % TSDR+ CD4-T cells (healthy controls):                    6.4 ±1.6%

TP= time point (TP1= week 6, TP2= week 14, TP3= week 22, TP4= week 36)

**Table 4 Clinical and immunological results: Overview**

Pt.#	Clinical response	TTP (weeks)	Immune response			
			DTH	peptide-specific	cytokine profile*	IL-10-release**
#1	SD	25	-	(+)	TH2	-
#2	PD	8	-	-		
#3	SD	69	-	(+)	TH1	-
#4	PD	18	-	-		
#5	SD	26	+	+	TH2 > TH1	+
#6	PD	9	-	+	TH2 > TH1	+
#7	PD	4	-	+	TH1 → TH2***	+
#8	SD	26	+	-		
#9	SD	58	+	+	TH2 > TH1	+
#10	PD	18	+	-		

SD= stable disease, PD= progressive disease, DTH= delayed type hypersensitivity reaction of the skin

\* = peptide-specific cytokine release on CBA/ predominant cytokine pattern (TH1 vs. TH2)

\*\* = induction of peptide-specific IL-10-release by the vaccine as measured by CBA

\*\*\* = shift from TH1 to TH2 during vaccination